Synthego Announces Successful Close of Acquisition by Perceptive Advisors
REDWOOD CITY, Calif., July 21, 2025 – Synthego, a leading provider of genome engineering solutions, today announced the successful completion of its acquisition by Perceptive Advisors, a prominent life sciences investment firm. The transaction marks a significant milestone for Synthego, ushering in a new era of growth and innovation with the strategic backing of a highly respected investor.
Perceptive Advisors’ acquisition of Synthego is expected to accelerate the company’s mission to empower researchers and clinicians with cutting-edge CRISPR-based tools and services. Synthego has established itself as a pioneer in the field of synthetic biology, offering a comprehensive suite of products and expertise that facilitate advancements in gene editing research, therapeutic development, and diagnostic innovation.
“We are thrilled to join forces with Perceptive Advisors,” said Kevin T. Parker, Chief Executive Officer of Synthego. “Perceptive’s deep understanding of the biotechnology landscape and their commitment to advancing life sciences innovation align perfectly with our vision. This partnership will provide us with the resources and strategic guidance to further expand our capabilities, enhance our product offerings, and ultimately, accelerate the translation of gene editing technologies into life-changing therapies and diagnostics.”
The acquisition by Perceptive Advisors is anticipated to enable Synthego to invest further in its research and development initiatives, expand its global commercial reach, and strengthen its position as a critical partner for the scientific community. Synthego’s commitment to quality, reliability, and customer support, which has been a cornerstone of its success, will continue to be a driving force under the new ownership.
“Synthego has demonstrated remarkable innovation and leadership in the rapidly evolving field of genome engineering,” commented Steven M. S. Chan, Managing Partner of Perceptive Advisors. “We are deeply impressed by Synthego’s advanced technological platform, its talented team, and its significant contributions to scientific discovery. We are confident that by leveraging our expertise and capital, we can help Synthego achieve its full potential and make an even greater impact on human health and scientific progress.”
Synthego’s extensive portfolio includes engineered CRISPR reagents, custom cell line engineering, and gene editing services, all designed to meet the rigorous demands of scientific research and therapeutic development. The company’s dedication to empowering scientists has fostered a strong reputation within the academic and biopharmaceutical sectors.
The successful closure of this acquisition signifies a positive outlook for the future of gene editing technologies and the role Synthego will play in shaping this transformative field. Researchers and industry partners can anticipate continued advancements and enhanced support as Synthego embarks on this new chapter.
Synthego Announces Successful Close of Acquisition by Perceptive Advisors
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Synthego Announces Successful Close of Acquisition by Perceptive Advisors’ at 2025-07-21 11:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.